
ANTONAZZO IPPAZIO COSIMO
Pubblicazioni
Antonazzo, I., Rozza, D., Cortesi, P., Fornari, C., Zanzottera Ferrari, E., Paris, C., et al. (2025). Generalizability and treatment with sodium-glucose co-trasporter-2 inhibitors (SGLT2i) among patients with type 2 diabetes: an assessment using an Italian primary care database. ACTA DIABETOLOGICA, 62(3), 343-351 [10.1007/s00592-024-02359-1]. Dettaglio
Mazzaglia, G., Antonazzo, I., Mol, P. (2024). Risk management and drug utilization research. In Drug Utilization Research: Methods and Applications (pp. 428-436). wiley [10.1002/9781119911685.ch42]. Dettaglio
Cortesi, P., Antonazzo, I., Palladino, P., Gnesi, M., Mele, S., D’Amelio, M., et al. (2024). Health and economic impact of dapagliflozin for type 2 diabetes patients who had or were at risk for atherosclerotic cardiovascular disease in the Italian general practitioners setting: a budget impact analysis. ACTA DIABETOLOGICA, 61(8), 1017-1028 [10.1007/s00592-024-02276-3]. Dettaglio
Ferrara, P., Antonazzo, I., Zamparini, M., Fornari, C., Borrelli, C., Boarino, S., et al. (2024). Epidemiology of SLE in Italy: an observational study using a primary care database. LUPUS SCIENCE & MEDICINE, 11(1) [10.1136/lupus-2024-001162]. Dettaglio
Brauer, M., Roth, G., Aravkin, A., Zheng, P., Abate, K., Abate, Y., et al. (2024). Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. THE LANCET, 403(10440 (18–24 May 2024)), 2162-2203 [10.1016/s0140-6736(24)00933-4]. Dettaglio